COMPANY ANNOUNCEMENT /  REGULATED INFORMATION / INSIDE INFORMATION
                                                                                                                             
IRVINE, CA, and HERSTAL, BELGIUM – 07:00 CEST, August 7, 2017 – MDxHealth SA (Euronext: MDXH.BR) today announced the appointment of Paul Marr as Executive Vice President of Sales for North America in conjunction with the expansion of its US sales force to 50 representatives.

Expansion of the US sales force to 50 representatives has been timed to address the Company’s mounting market opportunity for its robust portfolio of molecular diagnostic tests for urology, including its lead product ConfirmMDx^®, its new SelectMDx^(TM) liquid biopsy test, and its recently launched liquid biopsy bladder cancer test, AssureMDx^(TM). Following the inclusion of ConfirmMDx in the NCCN guidelines in 2016, the recent award of the Government Services Agreement in 2017 and in preparation for the effective date of the unique CPT billing code in 2018, the Company will be well-positioned to drive broader market adoption and revenue growth. Additionally, with a large and growing customer base, SelectMDx and AssureMDx are expected to gain rapid market adoption, so the expanded sales force will enable increased frequency of client visits to drive and support growth.

Mr. Marr is a senior healthcare executive with more than 20 years of sales leadership experience in clinical diagnostics. Most recently he served as Vice President of Sales, North America at Beckman Coulter, a Danaher Company. Previously, Mr. Marr has served in senior leadership positions in several multi-national diagnostic companies, including Hologic, Gen-Probe, Leica Biosystems, Bayer Diagnostics and Siemens Healthcare where he consistently achieved revenue growth. Mr. Marr started his career serving 8 years in the United States Navy, concluding his service as a Naval Special Operations Officer.  

 “This is a remarkable success story, with an impressive portfolio of best-in-class proprietary molecular diagnostic products, MDxHealth has established itself as a market leading brand in the field of urology,” stated Paul Marr, EVP of Sales, MDxHealth. “The management team has built a solid foundation, so I am excited to help the Company capitalize during this new phase of growth.”

“This is an exciting period for MDxHealth and I am very pleased to welcome Paul to our US Executive Leadership Team,” commented Dr. Jan Groen, CEO, MDxHealth. “Paul’s success in leading large sales teams, coupled with his experience in medical diagnostic sales in the North American market, will be invaluable as we take the business to the next level and capitalize on the $3 billion market opportunity in urology.”

About MDxHealth

MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The Company’s European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and US headquarters and laboratory operations based in Irvine, California. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth.

For more information:

Shalon Roth, EVP Corporate Communications
MDxHealth
+44 (0)7393 906278
shalon.roth@mdxhealth.com

This company announcement contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company’s control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this announcement to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation.  This company announcement does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.

NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx, SelectMDx, AssureMDx, PredictMDx and UrNCollect are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.